Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGAM | O43451 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | SI | P14410 | 2/20 | 0.40 |
| ▸ | MGAM2 | Q2M2H8 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | BCHE | P06276 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | KDM6B | O15054 | 1/20 | 0.31 |
| ▸ | KDM5C | P41229 | 1/20 | 0.31 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.31 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.31 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26740129 | 0.81 | MGAM (0.37) | MGAMGAASIMGAM2ALDH1A1 | |
| SCHEMBL6634064 | 0.80 | LDHA (0.38) | MGAMGAASIMGAM2ALDH1A1 | |
| SCHEMBL28340895 | 0.79 | ALDH1A1 (0.42) | ALDH1A1LMNAACHETSHR | |
| SCHEMBL10575074 | 0.78 | MGAM (0.44) | MGAMGAASIMGAM2ALDH1A1 | |
| SCHEMBL23165292 | 0.77 | CYP1A2 (0.36) | MGAMGAASIMGAM2ALDH1A1 | |
| SCHEMBL9411637 | 0.77 | MGAM (0.42) | MGAMGAASIMGAM2ALDH1A1 | |
| SCHEMBL8838659 | 0.77 | MGAM (0.48) | MGAMGAASIMGAM2ALDH1A1 | |
| SCHEMBL138841 | 0.76 | GAA (0.61) | MGAMGAASIMGAM2ALDH1A1 | |
| SCHEMBL10389028 | 0.76 | MGAM (0.30) | MGAMGAASIMGAM2 | |
| SCHEMBL178955 | 0.76 | THRB (0.40) | MGAMGAASIMGAM2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230357134-A1 | AGENTS FOR USE IN THE TREATMENT OF AMYLOIDOSIS | UCL BUSINESS LTD (GB) | 2023-11-09 | — | — | US | disclosed |
| US-20230357134-A1 | AGENTS FOR USE IN THE TREATMENT OF AMYLOIDOSIS | UCL BUSINESS LTD (GB) | 2023-11-09 | — | — | US | disclosed |
| EP-4214189-A1 | AGENTS FOR USE IN THE TREATMENT OF AMYLOIDOSIS | UCL Business Ltd (GB) | 2023-07-26 | — | — | EP | disclosed |
| WO-2022058733-A1 | AGENTS FOR USE IN THE TREATMENT OF AMYLOIDOSIS | UCL BUSINESS PLC (GB) | 2022-03-24 | — | — | WO | disclosed |
| US-20140205537-A1 | LRRK2 INHIBITORS | ZENOBIA THERAPEUTICS, INC. (US) | 2014-07-24 | — | — | US | disclosed |
| WO-2012178015-A2 | LRRK2 INHIBITORS | ZENOBIA THERAPEUTICS, INC. (US) | 2012-12-27 | — | — | WO | disclosed |
| US-6562833-B1 | Treating the fungi or the plants, seeds, material or the soil to be protected against fungal infection with a fungicidally effective amount of at least one 2-(N-phenylamino)pyrimidine | BASF AKTIENGESELLSCHAFT (DE) | 2003-05-13 | — | — | US | disclosed |
| EP-1085807-B1 | USE OF 2-(N-PHENYLAMINO)PYRIMIDINES AS FUNGICIDES, AND NOVEL 2-(N-PHENYLAMINO)PYRIMIDINES | BASF AG (DE) | 2003-05-07 | — | — | EP | disclosed |
| US-6297374-B1 | Nitroimino-nitromethylene—azole or-azine heterocyclic compounds, insecticidal compositions containing them, and insecticidal methods of using them | NIHON BAYER AGROCHEM K.K. (JP) | 2001-10-02 | — | — | US | disclosed |
| US-6022967-A | 1-NITRO-2-CARBOXYVINYL- OR 1-NITRO-2-(DIMETHYLAMINO)VINYL-SUBSTITUTED IMIDAZOLIDINES OR TETRAHYDROPYRIMIDINES | NIHON BAYER AGROCHEM K.K. (JP) | 2000-02-08 | — | — | US | disclosed |
| US-5412109-A | Process for preparing optically active 4-methyl-2-oxetanone | TAKASAGO INTERNATIONAL CORPORATION (JP) | 1995-05-02 | — | — | US | disclosed |
| US-5346899-A | Fungicides especially effective against ascomycetes and basidomycetes | BASF AKTIENGESELLSCHAFT (DE) | 1994-09-13 | — | — | US | disclosed |
| US-5306834-A | Catalytic hydrogenation of 4-methylene-2-oxetanone | TAKASAGO INTERNATIONAL CORPORATION (JP) | 1994-04-26 | — | — | US | disclosed |
| US-5298507-A | Insecticides | NIHON BAYER AGROCHEM K.K. (JP) | 1994-03-29 | — | — | US | disclosed |
| EP-0580336-A1 | Process for preparing optically active 4-methyl-2-oxetanone | TAKASAGO INTERNATIONAL CORPORATION (JP) | 1994-01-26 | — | — | EP | disclosed |
| US-5204360-A | Insecticides | NIHON BAYER AGROCHEM K.K. (JP) | 1993-04-20 | — | — | US | disclosed |
| US-5001138-A | Insecticides | NIHON TOKUSHU NOYAKU SEIZO, K.K. (JP) | 1991-03-19 | — | — | US | disclosed |
| US-4845106-A | INSECTICIDES | NIHON TOKUSHU NOYAKU SEIZO K.K. (JP) | 1989-07-04 | — | — | US | disclosed |
| US-4742060-A | 2-(NITROIMINO)- OR 2-(NITROMETHYLENE)-IMIDAZOLIDINES AS INSECTICIDES | NIHON TOKUSHU NOYAKU SEIZO K. K. (JP) | 1988-05-03 | — | — | US | disclosed |
| EP-0192060-A1 | Heterocyclic compounds | NIHON BAYER AGROCHEM K.K. (JP) | 1986-08-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140205537-A1 | LRRK2 INHIBITORS | LRRK2, PARK7, MAP2 | MGAM 4176/4885GAA 872/4885SI 4482/4885 |
| US-20230357134-A1 | AGENTS FOR USE IN THE TREATMENT OF AMYLOIDOSIS | TTR, C1R, APOB | MGAM 1208/4885GAA 202/4885SI 1704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.